



NDA 008372/S-088

SUPPLEMENT APPROVAL

Mallinckrodt Pharmaceuticals Ireland Limited
Attention: Tina Lee
Sr. Director, Regulatory Affairs
440 Route 22 East Suite 302
Bridgewater, NJ 08807

Dear Tina Lee:

Please refer to your supplemental new drug application (sNDA) dated and received September 1, 2026, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Acthar Gel (repository corticotropin injection).

We also refer to our letter dated August 3, 2026, notifying you, under Section 505(o)(4) of the FD&C Act, of new safety information that we have determined should be included in the labeling for adrenocorticotrophic hormone (ACTH) products. This information pertains to the risk of drug hypersensitivity.

This supplemental new drug application provides for revisions to the labeling for Acthar Gel consistent with our August 3, 2026, letter.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

Information on submitting SPL files using eList may be found in guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format-Promotional Labeling and Advertising Materials for Human Prescription Drugs*.

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.³ Information and Instructions for completing the form can be found at FDA.gov.⁴

[NOTE: The use of the term “new safety-related information” below includes new safety information (NSI) as described in section 505-1(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355-1(b)) and other safety-related information unrelated to section 505(o)(4) of the FD&C Act.]

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety-related information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety-related information that appears in the revised labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4).

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

³ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, contact Jemini Patel, Regulatory Project Manager, at Jemini.Patel@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Julie Goldrich, MD
Deputy Director for Safety
Division of Neurology 1
Office of Neuroscience
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JULIE W GOLDRICH
10/05/2026 11:35:41 AM